206. ASCO 2026 - Part 1

ASCO 2026 is done, and Michael and Josh have created a marathon episode for you all. This week we cover "Agents of the Present", where we summarise all the important trials with updates, overall survival and progression-free survival data that could influence your practice.

They cover immunotherapy, lifestyle interventions, pan-PI3K inhibitors, rare cancers (such as uveal melanoma), and antibody drug conjugates, to name a few. All the cancer types are covered, including genitourinary, gynaecological cancers, breast, colorectal, lung and lifestyle interventions!

Two more episodes to come!

Studies Discussed in this Episode

EV-302 Extended Follow-Up

ROSELLA (Ovarian Cancer)

RAMPART (Adjuvant RCC)

VIKTORIA-1 (HR +ve Breast Cancer)

OptimUM

OPTIMA (Breast Cancer)

Anbenitimab and Chemotherapy (HER2 +ve Breast Cancer)

TALAPRO-3 (Prostate Cancer)